Crossmark

Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival

Crossref DOI link: https://doi.org/10.1186/1471-2407-14-462

Published Online: 2014-06-21

Published Print: 2014-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kiba, Takayoshi

Ito, Takuo

Nakashima, Toshihisa

Okikawa, Yoshiko

Kido, Miki

Kimura, Akiko

Kameda, Keita

Miyamae, Fumiaki

Tanaka, Suzuko

Atsumi, Misao

Sumitani, Yoko

Shitakubo, Yoshimi

Niimi, Hiromasa
License Information

License valid from 2014-06-21